ASC Sales Strategy: Adapting MedTech for the 2026 Procedure Shift

This episode explores the strategic pivot required for MedTech companies as over 500 surgical procedures shift to Ambulatory Surgery Centers (ASCs) by 2026. We break down why traditional hospital-focused sales models are failing in the high-efficiency ASC environment and outline the new logistics, pricing, and value propositions needed to succeed in this rapidly growing market. - Why is the 2026 procedural shift to ASCs a critical challenge for MedTech sales teams? - How do purchasing decisions in an ASC differ from those in a hospital? - What common mistakes do hospital-focused sales teams make when approaching ASCs? - What are the essential logistics and pricing models required for the ASC environment? - How can you tailor your value proposition to appeal directly to surgeon-owners? - Is your company prepared for the addition of over 500 procedures to the ASC-approved list? - What specific strategies will win in the competitive Ambulatory Surgery Center market? Pure Global offers end-to-end regulatory consulting to help MedTech companies capitalize on market shifts like the move to ASCs. Our experts develop efficient regulatory strategies and conduct market research to identify the best pathways for expansion. By combining local expertise in over 30 markets with advanced AI tools, we streamline the process of getting your product approved and ready for sale. Whether you're a startup or a multinational, we help you navigate complex environments and optimize your product portfolio for new opportunities. Contact us at [e-mail] or visit https://pureglobal.com. Explore our free AI tools and database at https://pureglobal.ai.